Dash Bio has raised a $30 million Series A led by Oak HC/FT to expand its pharma lab services platform, aiming to provide research and operational support to biotechnology and pharmaceutical teams. The company’s fundraising highlights continued investor appetite for operational and workflow infrastructure in drug development, particularly where specialized services can shorten timelines or reduce execution friction. As markets remain selective on clinical risk, financing for enabling service models continues to attract capital when tied to measurable execution capabilities. For biotech operators, the round signals more capacity in outsourced lab functions that can complement in-house discovery and preclinical programs.